Literature DB >> 34322716

The role of CDHR3 in susceptibility to otitis media.

Scott D Hirsch1, Christina L Elling1, Tori C Bootpetch1, Melissa A Scholes1,2, Lena Hafrén3, Sven-Olrik Streubel1,2, Harold S Pine4, Todd M Wine1,2, Wasyl Szeremeta4, Jeremy D Prager1,2, Elisabet Einarsdottir5,6,7, Ayesha Yousaf8, Erin E Baschal1, Sakina Rehman9, Michael J Bamshad10, Deborah A Nickerson10, Saima Riazuddin9, Suzanne M Leal11, Zubair M Ahmed9, Patricia J Yoon1,2, Juha Kere5,6, Kenny H Chan1,2, Petri S Mattila3, Norman R Friedman1,2, Tasnee Chonmaitree12, Daniel N Frank13, Allen F Ryan14, Regie Lyn P Santos-Cortez15,16.   

Abstract

Otitis media (OM) is common in young children and can cause hearing loss and speech, language, and developmental delays. OM has high heritability; however, little is known about OM-related molecular and genetic processes. CDHR3 was previously identified as a locus for OM susceptibility, but to date, studies have focused on how the CDHR3 p.Cys529Tyr variant increases epithelial binding of rhinovirus-C and risk for lung or sinus pathology. In order to further delineate a role for CDHR3 in OM, we performed the following: exome sequencing using DNA samples from OM-affected individuals from 257 multi-ethnic families; Sanger sequencing, logistic regression and transmission disequilibrium tests for 407 US trios or probands with OM; 16S rRNA sequencing and analysis for middle ear and nasopharyngeal samples; and single-cell RNA sequencing and differential expression analyses for mouse middle ear. From exome sequence data, we identified a novel pathogenic CDHR3 splice variant that co-segregates with OM in US and Finnish families. Additionally, a frameshift and six missense rare or low-frequency variants were identified in Finnish probands. In US probands, the CDHR3 p.Cys529Tyr variant was associated with the absence of middle ear fluid at surgery and also with increased relative abundance of Lysobacter in the nasopharynx and Streptomyces in the middle ear. Consistent with published data on airway epithelial cells and our RNA-sequence data from human middle ear tissues, Cdhr3 expression is restricted to ciliated epithelial cells of the middle ear and is downregulated after acute OM. Overall, these findings suggest a critical role for CDHR3 in OM susceptibility. KEY MESSAGES: • Novel rare or low-frequency CDHR3 variants putatively confer risk for otitis media. • Pathogenic variant CDHR3 c.1653 + 3G > A was found in nine families with otitis media. • CDHR3 p.Cys529Tyr was associated with lack of effusion and bacterial otopathogens. • Cdhr3 expression was limited to ciliated epithelial cells in mouse middle ear. • Cdhr3 was downregulated 3 h after infection of mouse middle ear.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CDHR3; Expression; Microbiome; Middle ear; Otitis media; rs6967330

Mesh:

Substances:

Year:  2021        PMID: 34322716      PMCID: PMC8541908          DOI: 10.1007/s00109-021-02118-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  48 in total

1.  Functional genomics of CDHR3 confirms its role in HRV-C infection and childhood asthma exacerbations.

Authors:  Jamie L Everman; Satria Sajuthi; Benjamin Saef; Cydney Rios; Ari M Stoner; Mari Numata; Donglei Hu; Celeste Eng; Sam Oh; Jose Rodriguez-Santana; Eszter K Vladar; Dennis R Voelker; Esteban G Burchard; Max A Seibold
Journal:  J Allergy Clin Immunol       Date:  2019-03-29       Impact factor: 10.793

2.  Explicet: graphical user interface software for metadata-driven management, analysis and visualization of microbiome data.

Authors:  Charles E Robertson; J Kirk Harris; Brandie D Wagner; David Granger; Kathy Browne; Beth Tatem; Leah M Feazel; Kristin Park; Norman R Pace; Daniel N Frank
Journal:  Bioinformatics       Date:  2013-09-10       Impact factor: 6.937

3.  Genetic background and the risk of otitis media.

Authors:  Lena Hafrén; Erna Kentala; Tiina M Järvinen; Eira Leinonen; Päivi Onkamo; Juha Kere; Petri S Mattila
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2011-10-21       Impact factor: 1.675

4.  Genetic susceptibility to severe childhood asthma and rhinovirus-C maintained by balancing selection in humans for 150 000 years.

Authors:  Mary B O'Neill; Guillaume Laval; João C Teixeira; Ann C Palmenberg; Caitlin S Pepperell
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

5.  Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era.

Authors:  Ravinder Kaur; Matthew Morris; Michael E Pichichero
Journal:  Pediatrics       Date:  2017-08-07       Impact factor: 7.124

6.  CDHR3 Asthma-Risk Genotype Affects Susceptibility of Airway Epithelium to Rhinovirus C Infections.

Authors:  Sarmila Basnet; Yury A Bochkov; Rebecca A Brockman-Schneider; Ine Kuipers; Scott W Aesif; Daniel J Jackson; Robert F Lemanske; Carol Ober; Ann C Palmenberg; James E Gern
Journal:  Am J Respir Cell Mol Biol       Date:  2019-10       Impact factor: 6.914

7.  The genetic component of middle ear disease in the first 5 years of life.

Authors:  Margaretha L Casselbrant; Ellen M Mandel; Howard E Rockette; Marcia Kurs-Lasky; Patricia A Fall; Charles D Bluestone; Robert E Ferrell
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-03

8.  A general framework for estimating the relative pathogenicity of human genetic variants.

Authors:  Martin Kircher; Daniela M Witten; Preti Jain; Brian J O'Roak; Gregory M Cooper; Jay Shendure
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

9.  Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections.

Authors:  Chao Tian; Bethann S Hromatka; Amy K Kiefer; Nicholas Eriksson; Suzanne M Noble; Joyce Y Tung; David A Hinds
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.